GSK says ‘well positioned’ to respond to US tariff threats

British drugmaker GlaxoSmithKline said Wednesday it is “well positioned” to respond to US President Donald Trump’s potential tariffs on pharmaceuticals and maintained its 2025 outlook. “The company is well positioned to respond to the potential financial impact of sector-specific tariffs, should they be implemented, with mitigation options identified,” GSK said in its first-quarter earnings statement.

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *